CDKN2A and melanoma: The aim of this study is to define a scoring system based on immunohistochemical antibodies designed to predict cases with various CDKN2A alterations in order to mitigate the costs related to standard genetic testing and classify multiple primary and familial melanoma patients based on their mutational status using cost-effective investigations.